Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing ...

The future of mental health treatment looks promising, with innovative companies at the forefront of this transformation.

Intra-Cellular Therapies presents Q1 figures on May 7. Analysts are expecting losses per share of $0.317. Watch Intra-Cellular Therapies stock price move in real-time ahead here. Intra-Cellular ...

ITCI stock results show that Intra-Cellular Therapies beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.More From InvestorPlace The #1 AI Investment Might ...

Aligning economic incentives with global health goals is not only a moral imperative but a practical necessity for economic ...

Analyst Ami Fadia of Needham maintained a Buy rating on Intra-Cellular Therapies (ITCI – Research Report), retaining the price target of $90.00. Ami Fadia’s rating is based on a strong performance in ...

NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused ...

Multiple sclerosis (MS) is recognized as one of the most prevalent neurological diseases among young adults, with symptoms typically emerging between ages 20 to 40 years. The condition is ...

Q1 GAAP EPS of -$0.16 beats by $0.17. Revenue of $144.9M (+52.0% Y/Y) beats by $3.46M. Fiscal 2024 Financial Outlook: Full year 2024 CAPLYTA net product sales guidance of $645 to $675 million ...

Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing ...

Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.46 per share a year ago. These ...